You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
CTDetailNew
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Appointment
Find a Condition or Treatment
Find a Doctor
Menu
MAIN
Back to Home
About Us
Corporate Profile
Visitor Information
Newsroom
Contact Us
Patient's Rights and Responsibilities
Events
Patient Care
Conditions & Treatments
Specialties & Services
Community Partners
Your Clinic Visit
Your Hospital Stay
E-Services
Research & Innovation
Research in CGH
Core Facilites
SingHealth Research
Education & Training
Undergraduate
Postgraduate
Professional Development
Projects & Collaborations
TRaCS
SingHealth Academy
Careers
Why Choose Us
Career Choices
Job Opportunities
Scholarship & Sponsorship
Career Events
Giving
Overview
Why Give
Get Involved
Your Gift at Work
Be Informed
Conditions & Treatments
Back to Home
Conditions & Treatments
Find a Doctor
Find a Medicine
Specialties & Services
Back to Home
Clinical Specialties
Nursing
Nursing Overview
Nurse-led Services in CGH
Specialty Nursing
Community Nursing
Allied Health Services
Specialist Centres / Services
Community Partners
Back to Home
Community Care Disciplines
Community Health Services
GP Resources
Your Clinic Visit
Back to Home
Visiting a Specialist
Visiting the Emergency Department
Patient Care Through Video Consultation
Outpatient Covid-19 Vaccination
Your Hospital Stay
Back to Home
Patient Journey
Support Groups
Advance Care Planning
E-Services
Back to Home
Make/Change Appointment
Billing & Payment
Financial Counselling Online
Medication Delivery Services
Request for Medical Report
Find a Doctor
Telehealth
Forms
Patient Feedback
Tender
Health Buddy
Home
to skip to the main content on a page
to skip to the main content on a page
About Us
Back to Home
Corporate Profile
Hospital Overview
Vision and Mission
CGH Senior Management
CGH 88th Anniversary
Our Heritage
Milestones
Awards & Achievements
Annual Reports
Visitor Information
Visiting A Patient
Getting to CGH
Getting around CGH
Food & Amenities
Newsroom
News Articles
News Release
Publications
Health Library
Contact Us
Useful Contact Numbers
Email Contacts
Patient Feedback
Check News About CGH
Patient's Rights and Responsibilities
PDPA
Whistle-blowing Policy
Events
Patient Care
Back to Home
Conditions & Treatments
Conditions & Treatments
Find a Doctor
Find a Medicine
Specialties & Services
Clinical Specialties
Nursing
Allied Health Services
Specialist Centres / Services
Community Partners
Community Care Disciplines
Community Health Services
GP Resources
Your Clinic Visit
Visiting a Specialist
Visiting the Emergency Department
Patient Care Through Video Consultation
Outpatient Covid-19 Vaccination
Your Hospital Stay
Patient Journey
Support Groups
Advance Care Planning
E-Services
Make/Change Appointment
Billing & Payment
Financial Counselling Online
Medication Delivery Services
Request for Medical Report
Find a Doctor
Telehealth
Forms
Patient Feedback
Tender
Health Buddy
Research & Innovation
Back to Home
Research in CGH
Core Facilites
Clinical Trials & Research Unit
Health Services Research
Office of Innovation
Shimadzu-CGH Clinomics Centre
Centre for Healthcare Assistive & Robotics Technology (CHART)
SingHealth Research
Education & Training
Back to Home
Undergraduate
Medical Undergraduate Education
Nursing
Allied Health
Postgraduate
Medical Postgraduate Education
Nursing
Allied Health
Professional Development
Continuing Medical Education
Changi Simulation Institute
Changi Surgical Skills Lab
Projects & Collaborations
TRaCS
About Us
ReXilience® Programme
Counselling Services
Resources
Events
Contact Us
SingHealth Academy
Careers
Back to Home
Why Choose Us
Working at CGH
Career Choices
Doctors
Nurses
Allied Health Professionals
Management & Administration
Ancillary & Support
Job Opportunities
Scholarship & Sponsorship
Healthcare Scholarship
CGH Sponsorship
Meet Our Students
FAQs
Career Events
Giving
Back to Home
Overview
Campaigns
CGH Health Fund
Changi Run 2024
Why Give
Empower Our Patients in Need
Advance Healthcare Excellence
Benefits of Giving
Get Involved
Ways to Give
Your Gift at Work
Be Informed
Honour Roll of Donors
Contact Us
Home
>
Patient Care
>
Conditions and Treatment
>
Lutetium-177 PSMA (LuPSMA) radionuclide therapy
Lutetium-177 PSMA (LuPSMA) radionuclide therapy
Facebook
WhatsApp
Email Us
share
Font Resize
A-
A
A+
Print
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - What it is
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Symptoms
Lutetium-177 PSMA radionuclide therapy is used for treating patients with advanced prostate cancer. Prostate cancers, in particular those that have spread to other sites of the body or become resistant to hormonal therapies, express a unique substance on their cell surface called prostate specific membrane antigen (PSMA). LuPSMA radionuclide therapy involves using a radioactive molecule (Lutetium-177) and PSMA substance that specifically attaches to cells with high PSMA expression. This radioactive molecule is taken up into prostate cancer cells, or wherever the disease has spread and enables delivery of high doses of targeted radiation to sites of prostate cancer whilst sparing most normal tissues. This is called radionuclide therapy as it uses radiation to kill prostate cancer cells.
Why do I need this treatment?
The use of LuPSMA therapy is largely for patients who have progressive metastatic hormone-resistant prostate cancer. You may be referred for this treatment if there is progression of your condition despite having undergone conventional therapy (such as hormonal treatment and chemotherapy). Hormonal treatment and other systemic therapies may control the disease for some periods of time, however many patients eventually suffer a relapse of the disease.
The benefits of this targeted radionuclide therapy may include shrinkage of tumours, a reduction in blood Prostate Specific Antigen (PSA) level, improvement in symptoms such as pain and a general improvement in well-being.
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - How to prevent?
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Causes and Risk Factors
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Diagnosis
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Treatments
What does it involve?
LuPSMA treatment is an outpatient treatment. It will be administered via an intravenous line into the veins of your arms.
You will receive up to 4 -6 cycles of LuPSMA treatment at 6-8 week intervals.
What precautions must I take for the treatment?
Standard supportive drugs, hormonal therapy, biosphosphonate therapy or palliative radiotherapy while on LuPSMA therapy is permissible as clinically indicated. Concurrent chemotherapy while receiving LuPSMA therapy is currently not permitted.
It is important to tell your doctor about any treatments or medications you may be taking, including over-the-counter medications, vitamins or herbal remedies, acupuncture or other alternative treatments, and any changes to these medications during your LuPSMA therapy.
What are the risks of the treatment?
Possible short term side effects (within weeks to months of treatment):
1. Nausea (very common: more than 1 in 10)
This is usually mild and, if needed, can be treated with anti-nausea medication.
2. Injury to salivary or lacrimal (tear) glands (very common: more than 1 in 10)
These gland cells have PSMA-receptors, which LuPSMA will attach to. Therefore, the glands will receive radiation. This may result in inflammation (swelling) of the glands which may lead to pain or decreased production of saliva and/or tears. This will most likely be temporary and resolve with time. Permanent injury (e.g. reduced production of saliva or tears) is possible but is usually mild and can be alleviated with artificial saliva and tear drops.
3. Increased pain or pressure effects from swelling due to radiation damage at sites of tumours (common: between 1 in 10 and 1 in 100)
This is usually temporary but may require increase in painkiller requirements.
4. Flu-like symptoms (common: between 1 in 10 and 1 in 100)
As tumours die, this can result in flu-like symptoms including low grade fevers and fatigue.
5. Bleeding or infection as a result of reduction in blood count (uncommon: likelihood of less than 1 in 100 to 1 in 1000)
The extent of blood count reduction may be influenced by prior therapies (e.g. chemotherapy). If you have very extensive bone metastases, this may also increase the likelihood of reduced blood count. Mild reduction in blood count that can be measured through blood tests without any resulting symptoms may be more common (between 1 in 10 and 1 in 100).
6. Kidney failure (uncommon: likelihood of less than 1 in 100 to 1 in 1000)
Reduced glomerular filtration rate of the kidneys has been observed following LuPSMA therapy, however this usually does not result in kidney dysfunction clinically for most patients.
Possible longer-term side effects
Longer-term side effects may include risk of developing secondary malignancies. The precise increase in risk is not known but thought to be very small (less than 1 in 100) and will depend somewhat on the radiation doses absorbed during the treatment. However, the risk of serious sequelae is relatively rare and typically involves blood disorders that may develop several years after treatment.
What can I expect after the treatment?
After each treatment, a whole body 2-dimensional scan and a more detailed 3-dimensional scan will be performed to see where the radiation has gone to. This scan will take approximately 45-60 minutes to complete. Most patients will feel well and be allowed to go home on the day of treatment.
However, you will be mildly radioactive for a few days and there may be some restrictions on close personal contact including with pregnant women or children.
Your blood will be taken and tested (full blood count, urea and electrolytes, liver function tests, PSA) at 14 and 28 days after the treatment.
Further LuPSMA treatments can be considered for patients who responded to initial cycles of LuPSMA but subsequently progressed, provided they continued to meet the eligibility criteria for treatment.
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Preparing for surgery
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Post-surgery care
Lutetium-177 PSMA (LuPSMA) radionuclide therapy - Other Information
Symptoms
Article contributed by
Nuclear Medicine and Molecular Imaging
,
Singapore General Hospital
The information provided is not intended as medical advice.
Terms of use
. Information provided by
Our Breast Team
Filter:
By designation or sub-specially
By Designation:
By Sub-Specialty:
TOP
[]
Related Medications
Healthy Living Tips
by
View more
Discover articles,videos, and guides afrom Singhealth's resources across the web. These information are collated, making healthy living much easier for everyone.
Managing Lower Back Pain - Doctor Q&A
Snoring When To See A Doctor
Post-Stroke Exercises (Lower Limb Strength Training)
Post-Stroke Exercises (Upper Limb Strength Training)
×
SUBSCRIBE VIA EMAIL
Subscribe to our mailing list to get the updates to your email inbox...
Find a Doctor
Condition & Treatment
Home
Appointment
E-services